Trial design of the GHSG HD16 and HD17 studies in early-stage HL. (A) HD16 trial in early-stage favorable HL with 1150 patients randomly assigned. (B) HD17 trial in early-stage unfavorable HL with 1009 patients randomly assigned. RFs were as follows: a, large mediastinal mass; b, extranodal disease; c, elevated erythrocyte sedimentation rate (with B symptoms, >30mm/h; without B symptoms, >50 mm/h); and d, ≥3 nodal areas. BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; FU, follow-up.